Abbisko Cayman Ltd
HKEX:2256

Watchlist Manager
Abbisko Cayman Ltd Logo
Abbisko Cayman Ltd
HKEX:2256
Watchlist
Price: 4.33 HKD -0.23% Market Closed
Market Cap: 2.9B HKD
Have any thoughts about
Abbisko Cayman Ltd?
Write Note

Gross Margin
Abbisko Cayman Ltd

100%
Current
83%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
100%
=
Gross Profit
497.3m
/
Revenue
497.3m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
CN
Abbisko Cayman Ltd
HKEX:2256
3B HKD
100%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
67%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
134.4B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
35.7B EUR
89%
Country CN
Market Cap 3B HKD
Gross Margin
100%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 310.3B USD
Gross Margin
67%
Country US
Market Cap 141.6B USD
Gross Margin
60%
Country US
Market Cap 115.3B USD
Gross Margin
78%
Country US
Market Cap 102.4B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 77.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 35.7B EUR
Gross Margin
89%
No Stocks Found

Abbisko Cayman Ltd
Glance View

Market Cap
3B HKD
Industry
Biotechnology

Abbisko Cayman Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-10-13. The firm is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The firm owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Intrinsic Value
2.41 HKD
Overvaluation 44%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
100%
=
Gross Profit
497.3m
/
Revenue
497.3m
What is the Gross Margin of Abbisko Cayman Ltd?

Based on Abbisko Cayman Ltd's most recent financial statements, the company has Gross Margin of 100%.